Bisichem Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, among others.
Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the treatment of pancreatic cancer, small-cell lung cancer, ovarian cancer, breast cancer and colorectal cancer.
Novel therapeutic strategies are needed to overcome drug resistance and ensure prolonged remission in multiple myeloma (MM) patients. The coactivator-associated arginine methyltransferase 1 (CARM1) is overexpressed in MM and correlated with poor prognosis and, therefore, has been proposed as a potential therapeutic target.
The TNF receptor superfamily member herpesvirus entry mediator (HVEM or TNFRSF14), first identified as a receptor for viral infection, acts as a molecular switch, either activating or inhibiting the immune response depending on the interacting ligand. Previous work found that HVEM binding to B- and T-lymphocyte attenuator (BTLA) initiates an inhibitory signal to effector T cells and that targeting the HVEM-BTLA complex with an antibody reduced tumor growth in a humanized mouse model.
Cancer Targeted Technology LLC has disclosed conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) targeting ligand covalently linked to a therapeutic or diagnostic agent through a linker reported to be useful for the treatment of prostate cancer.
Cholangiocarcinoma includes several biliary malignant tumors that have poor prognosis. Post-translational modifications in proteins lead to abnormal protein dynamics and disturbances that may cause pathology.
RSS
